INSTI相关体重增加的多组学代谢机制:男性HIV感染者研究
该研究对64例男性HIV感染者及26例健康男性对照进行纵向血浆非靶向代谢组学和蛋白质组学分析,按治疗史和第一年体重变化分为三组。结果发现转换至INSTI导致普遍性低代谢状态,表现为甲状腺素下降和N-乙酰腐胺升高,与体重结局无关;蛋白质组学识别出体重增加组特有的分子驱动因素,随机森林模型显示前INSTI多组学特征中TTR是最强预测生物标志物。
要点
- INSTI方案引发普遍性低代谢状态,甲状腺素下降、N-乙酰腐胺升高,不依赖体重变化。
- 蛋白质组学识别出体重增加组特有的分子驱动因素。
- 前INSTI多组学特征中TTR是体重增加的最强预测生物标志物。
核心结论
- 基于INSTI的方案诱导普遍性代谢改变,甲状腺素代谢在INSTI相关体重增加中起关键作用。
研究设计与样本
- 多组学研究纳入64例男性HIV感染者,按治疗史和第一年体重变化分为G1(接受INSTI且体重增加≥5%)、G2(转换至INSTI且体重增加≥5%)、G3(转换至INSTI无体重增加),另纳入26例健康男性对照。
- INSTI方案包括比克替拉韦、艾维雷韦和多替拉韦组合,纵向分析血浆非靶向代谢组学和蛋白质组学,并采用机器学习模型整合多组学数据识别预测生物标志物。
主要发现
- 代谢组学分析显示转换至INSTI诱导普遍性低代谢状态,所有转换组均出现甲状腺素下降和N-乙酰腐胺升高,与体重结局无关。
- 蛋白质组学分析识别出体重增加组特有的分子驱动因素。
- 随机森林模型显示前INSTI多组学特征中TTR是最强预测生物标志物。
临床怎么用
- 对于接受INSTI方案的男性HIV感染者,可关注甲状腺素代谢相关指标及TTR作为体重增加的潜在预测标志物。
局限性
- 研究仅纳入男性HIV感染者,结论可能不适用于女性。
- 样本量较小(64例PWH和26例对照),需更大规模研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Integrase Strand Transfer Inhibitors (INSTI) are recommended as first-line antiretroviral therapy (ART) for HIV infection, yet are frequently associated with excessive weight gain. METHODS: We conducted a multi-omics study on male people with HIV (PWH). A total of 64 male PWH were enrolled and stratified based on their therapeutic history and weight changes over the first year (G1 receiving INSTI with weight gain ≥ 5%; G2 switching to INSTI with weight gain ≥ 5%; and G3 switching to INSTI without weight gain). INSTI-based regimens included bictegravir-, elvitegravir-, and dolutegravir-containing combinations. 26 healthy male controls were also included. Plasma untargeted metabolomics and proteomics were analyzed longitudinally. Machine learning models were employed to integrate multi-omics data and identify predictive biomarkers. RESULTS: Metabolomic analysis revealed that switching to INSTI induced a generalized hypometabolic state, characterized by a universal decline in thyroxine and an increase in N-acetylputrescine across all switching groups, independent of weight outcomes. In contrast, proteomic profiling identified distinct molecular drivers specific to the weight-gain groups. Random forest modeling identified transthyretin (TTR) as the top predictive biomarker among pre-INSTI multi-omics features. CONCLUSION: Our integrated multi-omics approach reveals that INSTI-based regimens induce universal metabolic changes. The change of thyroxine and the predictability of TTR in multi-omic studies show the critical role of thyroxine metabolism in INSTI-associated weight gain.
引用
- Huang X, Wang Z, Wang Y, et al. Metabolic Mechanisms of INSTI-Associated Weight Gain: A Multi-Omics Study in Male People with HIV. J Infect Dis. 2026. PMID: 42507986. doi:10.1093/infdis/jiag385
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。